03 August 2018
Visiongain has launched a new pharma report Global Contraceptive Devices Market Forecast to 2027: Male Condoms, Female Condoms, Diaphragms, Sponges, Vaginal Rings, Subdermal/Contraceptive Implants, Intra-uterine Devices (IUDs), Copper IUD, Hormonal IUD
The evolution of contraceptive devices has opened a new outlook in the healthcare industry. Growth rate exhibited by the contraceptive devices market despite the shortages and lack of awareness among the population in various countries, confirms the positive growth prospects going ahead. The contraceptive devices market is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as condoms, diaphragms, vaginal rings, sponges, etc.
The lead analyst of the report commented “The global contraceptive devices market is expected to experience a significant growth over the forecast period. The main drivers for the growth include rapid growth in population, development of technologically advanced contraceptive devices, huge burden of sexually transmitted diseases and HIV, increasing adoption of contraceptive devices and supportive government authorities.
The rising prevalence of sexually transmitted diseases (STDs) is increasing the need of more innovative products in the contraceptive devices market. At present, condoms are the only contraceptive devices that prevent from the risk of sexually transmitted infections & HIV therefore; manufacturers across the globe are enormously investing in R&D to come up with a product that would be reminiscent of contraceptive condoms in the prevention of sexually transmitted infections & HIV along with unintended pregnancies and birth control.”
Leading companies featured in the report include Bayer AG, Reckitt Benckiser Group plc
Merck Sharp & Dohme Corp., Church & Dwight Co., Inc., Teva Pharmaceutical Industries, Ltd.
Allergan plc, Ansell Limited (Now Humanwell), The Female Health Company (a division of VERU Inc.), Karex Industries, Mayer Laboratories, Kessel Medintim GmbH, Okamato Industries, Inc., Agile Therapeutics, Inc., Eurogine S.L.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.